A newspaper report revealed south china post About the UAE’s approval to launch experiments on the Chinese Corona vaccine YishengBio For therapeutic use, patients with mild to moderate corona infection will be targeted first in the vaccine trial, which includes two doses seven days apart, and the Chinese corona vaccine, which completes its dose within a week, has been approved for trial in the United Arab Emirates as a preventive and curative option.
According to the report, the UAE approved the therapeutic use of human trials of the vaccine developed by the company YishengBio It is based in Beijing, with efficacy studies conducted on mild to moderate infections of the Corona virus first.
This comes after the UAE Ministry of Health also approved last month the first phase of human trials for the preventive use of the vaccine, as did the New Zealand Medical Regulatory Authority, and human trials will be conducted in partnership with the UAE and New Zealand Clinical Pharmaceutical Development Company.
David Shao, CEO of YishengBio It is expected that recruitment of participants for the trial in New Zealand will begin soon, while requests for clinical trials are underway in more countries, and he said that preclinical studies have shown that the vaccine is able to induce rapid and high levels of antibodies and cellular immunity.
In a preclinical study of non-human primates, monkeys were infected with the coronavirus first before being injected with what Shaw called the country’s first therapeutic coronavirus vaccine with “promising results.”
The new Chinese vaccine
“The vaccine can stimulate cellular immunity,” Shao added. “We have found good results in animal studies, which is why we also obtained approval for the relevant evaluation by the UAE Ministry of Health.”.
Vaccine targets YishengBio Recombinant protein dependent on the high protein of the coronavirus and includes an independently developed adjuvant, a compound that enhances the effect of the immune response to vaccines, and the recombinant technology includes the development of DNA coding for the antigen of the Corona virus, which stimulates the immune response.
Shao said that the adjuvant PIKA The patents were in part because the vaccine needed only a seven-day time period between the two required doses..
He emphasized, “We have developed a material PIKA Help for more than 10 years, it has been used in hepatitis vaccines B As well as the rabies vaccine, which is undergoing human trials in the early stages, and immuno-oncology treatment products… We have used the Corona vaccine with this substance and the result is also good.”
Shao said animal serum studies have shown that YishengBio vaccine can provide broad and lasting protection against coronavirus variants including Alpha, Beta, Gamma and Lambda even at day 448 after vaccination, indicating good robustness of the immune response with only one week to complete. doses, and the vaccine is likely to be very useful during an outbreak.
Shao added that the company hopes to explore application prospects through “rigorous clinical trials” that can test whether vaccines can induce a rapid and robust immune response in humans, with a lasting effect and broader protection from various variants as demonstrated in animal experiments..
Shao stressed that early and late trials will be held abroad because the virus is not prevalent in China, adding that the near-completion production facility in Shenyang, northeast China’s Liaoning Province, will be able to deploy up to one billion doses a year.